Global Consortium Study of Neurological Dysfunction in COVID-19 (GCS-NeuroCOVID): Study Design and Rationale.
COVID-19
Coronavirus
Neurological manifestations
Neurological symptoms
SARS-CoV-2
Journal
Neurocritical care
ISSN: 1556-0961
Titre abrégé: Neurocrit Care
Pays: United States
ID NLM: 101156086
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
pubmed:
24
5
2020
medline:
18
8
2020
entrez:
24
5
2020
Statut:
ppublish
Résumé
As the COVID-19 pandemic developed, reports of neurological dysfunctions spanning the central and peripheral nervous systems have emerged. The spectrum of acute neurological dysfunctions may implicate direct viral invasion, para-infectious complications, neurological manifestations of systemic diseases, or co-incident neurological dysfunction in the context of high SARS-CoV-2 prevalence. A rapid and pragmatic approach to understanding the prevalence, phenotypes, pathophysiology and prognostic implications of COVID-19 neurological syndromes is urgently needed. The Global Consortium to Study Neurological dysfunction in COVID-19 (GCS-NeuroCOVID), endorsed by the Neurocritical Care Society (NCS), was rapidly established to address this need in a tiered approach. Tier-1 consists of focused, pragmatic, low-cost, observational common data element (CDE) collection, which can be launched immediately at many sites in the first phase of this pandemic and is designed for expedited ethical board review with waiver-of-consent. Tier 2 consists of prospective functional and cognitive outcomes assessments with more detailed clinical, laboratory and radiographic data collection that would require informed consent. Tier 3 overlays Tiers 1 and 2 with experimental molecular, electrophysiology, pathology and imaging studies with longitudinal outcomes assessment and would require centers with specific resources. A multicenter pediatrics core has developed and launched a parallel study focusing on patients ages <18 years. Study sites are eligible for participation if they provide clinical care to COVID-19 patients and are able to conduct patient-oriented research under approval of an internal or global ethics committee. Hospitalized pediatric and adult patients with SARS-CoV-2 and with acute neurological signs or symptoms are eligible to participate. The primary study outcome is the overall prevalence of neurological complications among hospitalized COVID-19 patients, which will be calculated by pooled estimates of each neurological finding divided by the average census of COVID-19 positive patients over the study period. Secondary outcomes include: in-hospital, 30 and 90-day morality, discharge modified Rankin score, ventilator-free survival, ventilator days, discharge disposition, and hospital length of stay. In a one-month period (3/27/20-4/27/20) the GCS-NeuroCOVID consortium was able to recruit 71 adult study sites, representing 17 countries and 5 continents and 34 pediatrics study sites. This is one of the first large-scale global research collaboratives urgently assembled to evaluate acute neurological events in the context of a pandemic. The innovative and pragmatic tiered study approach has allowed for rapid recruitment and activation of numerous sites across the world-an approach essential to capture real-time critical neurological data to inform treatment strategies in this pandemic crisis.
Sections du résumé
BACKGROUND
As the COVID-19 pandemic developed, reports of neurological dysfunctions spanning the central and peripheral nervous systems have emerged. The spectrum of acute neurological dysfunctions may implicate direct viral invasion, para-infectious complications, neurological manifestations of systemic diseases, or co-incident neurological dysfunction in the context of high SARS-CoV-2 prevalence. A rapid and pragmatic approach to understanding the prevalence, phenotypes, pathophysiology and prognostic implications of COVID-19 neurological syndromes is urgently needed.
METHODS
The Global Consortium to Study Neurological dysfunction in COVID-19 (GCS-NeuroCOVID), endorsed by the Neurocritical Care Society (NCS), was rapidly established to address this need in a tiered approach. Tier-1 consists of focused, pragmatic, low-cost, observational common data element (CDE) collection, which can be launched immediately at many sites in the first phase of this pandemic and is designed for expedited ethical board review with waiver-of-consent. Tier 2 consists of prospective functional and cognitive outcomes assessments with more detailed clinical, laboratory and radiographic data collection that would require informed consent. Tier 3 overlays Tiers 1 and 2 with experimental molecular, electrophysiology, pathology and imaging studies with longitudinal outcomes assessment and would require centers with specific resources. A multicenter pediatrics core has developed and launched a parallel study focusing on patients ages <18 years. Study sites are eligible for participation if they provide clinical care to COVID-19 patients and are able to conduct patient-oriented research under approval of an internal or global ethics committee. Hospitalized pediatric and adult patients with SARS-CoV-2 and with acute neurological signs or symptoms are eligible to participate. The primary study outcome is the overall prevalence of neurological complications among hospitalized COVID-19 patients, which will be calculated by pooled estimates of each neurological finding divided by the average census of COVID-19 positive patients over the study period. Secondary outcomes include: in-hospital, 30 and 90-day morality, discharge modified Rankin score, ventilator-free survival, ventilator days, discharge disposition, and hospital length of stay.
RESULTS
In a one-month period (3/27/20-4/27/20) the GCS-NeuroCOVID consortium was able to recruit 71 adult study sites, representing 17 countries and 5 continents and 34 pediatrics study sites.
CONCLUSIONS
This is one of the first large-scale global research collaboratives urgently assembled to evaluate acute neurological events in the context of a pandemic. The innovative and pragmatic tiered study approach has allowed for rapid recruitment and activation of numerous sites across the world-an approach essential to capture real-time critical neurological data to inform treatment strategies in this pandemic crisis.
Identifiants
pubmed: 32445105
doi: 10.1007/s12028-020-00995-3
pii: 10.1007/s12028-020-00995-3
pmc: PMC7243953
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
25-34Subventions
Organisme : NINDS NIH HHS
ID : R21 NS113037
Pays : United States
Références
Asadi-Pooya AA, Simani L. Central nervous system manifestations of COVID-19: a systematic review. J Neurol Sci. 2020;413:116832.
pubmed: 32299017
pmcid: 7151535
doi: 10.1016/j.jns.2020.116832
Poyiadji N, et al. COVID-19-associated acute hemorrhagic necrotizing encephalopathy: CT and MRI features. Radiology. 2020;1201187.
Li Y, Wang M, Zhou Y, Jiang C, Xian Y, Mao L, Hong C, Chen S, Wang Y, Wang H, Li M, Jin H, Hu B. Acute cerebrovascular disease following COVID-19: a single center, retrospective, observational study. The Lancet. 2020 (preprint).
Toscano G, et al. Guillain–Barre syndrome associated with SARS-CoV-2. N Engl J Med. 2020.
Wu Y, et al. Nervous system involvement after infection with COVID-19 and other coronaviruses. Brain Behav Immun. 2020.
Mao L, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020.
Klok FA, et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis. Thromb Res. 2020.
Zhao H, et al. Guillain–Barre syndrome associated with SARS-CoV-2 infection: causality or coincidence? Lancet Neurol. 2020;19(5):383–4.
pubmed: 32246917
pmcid: 7176927
doi: 10.1016/S1474-4422(20)30109-5
Sedaghat Z, Karimi N. Guillain Barre syndrome associated with COVID-19 infection: a case report. J Clin Neurosci. 2020.
Camdessanche JP, et al. COVID-19 may induce Guillain–Barre syndrome. Rev Neurol (Paris). 2020.
Virani A, et al. Guillain–Barre syndrome associated with SARS-CoV-2 infection. IDCases. 2020; e00771.
Alberti P, et al. Guillain–Barre syndrome related to COVID-19 infection. Neurol Neuroimmunol Neuroinflamm. 2020;7(4).
Padroni M, et al. Guillain–Barre syndrome following COVID-19: new infection, old complication? J Neurol. 2020.
Moriguchi T, et al. A first case of meningitis/encephalitis associated with SARS-coronavirus-2. Int J Infect Dis. 2020;94:55–8.
pubmed: 32251791
pmcid: 7195378
doi: 10.1016/j.ijid.2020.03.062
Helms J, et al. Neurologic features in severe SARS-CoV-2 infection. N Engl J Med. 2020.
Needham EJ, et al. Neurological implications of COVID-19 infections. Neurocrit Care. 2020.
Hung EC, et al. Detection of SARS coronavirus RNA in the cerebrospinal fluid of a patient with severe acute respiratory syndrome. Clin Chem. 2003;12:2108–9.
doi: 10.1373/clinchem.2003.025437
He L, et al. Expression of the monoclonal antibody against nucleocapsid antigen of SARS-associated coronavirus in autopsy tissues from SARS patients. Di Yi Jun Yi Da Xue Xue Bao. 2003;23(11):1128–30.
pubmed: 14625168
Hwang CS. Olfactory neuropathy in severe acute respiratory syndrome: report of A case. Acta Neurol Taiwan. 2006;15(1):26–8.
pubmed: 16599281
Yu F, et al. Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan. China. Microbes Infect. 2020;22(2):74–9.
pubmed: 32017984
doi: 10.1016/j.micinf.2020.01.003
Xu J, et al. Detection of severe acute respiratory syndrome coronavirus in the brain: potential role of the chemokine mig in pathogenesis. Clin Infect Dis. 2005;41(8):1089–96.
pubmed: 16163626
doi: 10.1086/444461
Ding Y, et al. Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways. J Pathol. 2004;203(2):622–30.
pubmed: 15141376
pmcid: 7167761
doi: 10.1002/path.1560
Netland J, et al. Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2. J Virol. 2008;82(15):7264–75.
pubmed: 18495771
pmcid: 2493326
doi: 10.1128/JVI.00737-08
Hoffmann M, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–280.e8.
pubmed: 32142651
pmcid: 7102627
doi: 10.1016/j.cell.2020.02.052
Qi J, Zhou Y, Hua J, Zhang L, Bian J, Liu B, Zhao Z, Jin S. The scRNA-seq expression profiling of the receptor ACE2 and the cellular protease TMPRSS2 reveals human organs susceptible to COVID-19 infection. bioRxiv. 2020.
Paniz-Mondolfi A, et al. Central nervous system involvement by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). J Med Virol. 2020.
Desforges M, et al. Human coronaviruses and other respiratory viruses: underestimated opportunistic pathogens of the central nervous system? Viruses. 2019;12(1):14.
pmcid: 7020001
doi: 10.3390/v12010014
Machado C, Gutierrez J. Brainstem dysfunction in SARS-COV2 infection can be a potential cause of respiratory distress. 2020 (preprints).
Filatov A, et al. Neurological complications of coronavirus disease (COVID-19): encephalopathy. Cureus. 2020;12(3):e7352.
pubmed: 32328364
pmcid: 7170017
Mlakar J, et al. Zika virus associated with microcephaly. N Engl J Med. 2016;374(10):951–8.
pubmed: 26862926
doi: 10.1056/NEJMoa1600651
Baltagi SA, et al. Neurological sequelae of 2009 influenza A (H1N1) in children: a case series observed during a pandemic. Pediatr Crit Care Med. 2010;11(2):179–84.
pubmed: 20081552
doi: 10.1097/PCC.0b013e3181cf4652
Messacar K, et al. Acute flaccid myelitis: a clinical review of US cases 2012–2015. Ann Neurol. 2016;80(3):326–38.
pubmed: 27422805
pmcid: 5098271
doi: 10.1002/ana.24730
Dong Y., et al. Epidemiology of COVID-19 among children in China. Pediatrics. 2020.
Aggarwal G, Lippi G, Michael Henry B. Cerebrovascular disease is associated with an increased disease severity in patients with coronavirus disease 2019 (COVID-19): a pooled analysis of published literature. Int J Stroke. 2020. 1747493020921664.
Nathan N, Prevost B, Corvol H. Atypical presentation of COVID-19 in young infants. Lancet. 2020.
Suarez JI, Macdonald RL. The end of the tower of babel in subarachnoid hemorrhage: common data elements at last. Neurocrit Care. 2019;30(Suppl 1):1–3.
pubmed: 31152313
doi: 10.1007/s12028-019-00751-2
Suarez JI, et al. Common data elements for unruptured intracranial aneurysms and subarachnoid hemorrhage clinical research: a national institute for neurological disorders and stroke and national library of medicine project. Neurocrit Care. 2019;30(Suppl 1):4–19.
pubmed: 31087257
doi: 10.1007/s12028-019-00723-6
Saver JL, et al. Standardizing the structure of stroke clinical and epidemiologic research data: the National Institute of Neurological Disorders and Stroke (NINDS) Stroke Common Data Element (CDE) project. Stroke. 2012;43(4):967–73.
pubmed: 22308239
pmcid: 3493110
doi: 10.1161/STROKEAHA.111.634352
Maas AI, et al. Common data elements for traumatic brain injury: recommendations from the interagency working group on demographics and clinical assessment. Arch Phys Med Rehabil. 2010;91(11):1641–9.
pubmed: 21044707
doi: 10.1016/j.apmr.2010.07.232
Chou SH, Macdonald RL, Keller E. Biospecimens and molecular and cellular biomarkers in aneurysmal subarachnoid hemorrhage studies: common data elements and standard reporting recommendations. Neurocrit Care. 2019;30(Suppl 1):46–59.
pubmed: 31144274
doi: 10.1007/s12028-019-00725-4
pmcid: 7888262
Hackenberg KAM, et al. Common data elements for radiological imaging of patients with subarachnoid hemorrhage: proposal of a multidisciplinary research group. Neurocrit Care. 2019;30(Suppl 1):60–78.
pubmed: 31115823
doi: 10.1007/s12028-019-00728-1
de Oliveira Manoel AL, et al. Common data elements for unruptured intracranial aneurysms and aneurysmal subarachnoid hemorrhage: recommendations from the working group on hospital course and acute therapies-proposal of a multidisciplinary research group. Neurocrit Care. 2019;30(Suppl 1):36–45.
pubmed: 31119687
doi: 10.1007/s12028-019-00726-3
Damani R, et al. Common data element for unruptured intracranial aneurysm and subarachnoid hemorrhage: recommendations from assessments and clinical examination workgroup/subcommittee. Neurocrit Care. 2019;30(Suppl 1):28–35.
pubmed: 31090013
doi: 10.1007/s12028-019-00736-1
Bijlenga P, et al. Common data elements for subarachnoid hemorrhage and unruptured intracranial aneurysms: recommendations from the working group on subject characteristics. Neurocrit Care. 2019;30(Suppl 1):20–7.
pubmed: 31077079
doi: 10.1007/s12028-019-00724-5
Hill AB. The environment and disease: association or causation? 1965. J R Soc Med. 2015;108(1):32–7.
pubmed: 25572993
pmcid: 4291332
doi: 10.1177/0141076814562718
Mortimer PP. Was encephalitis lethargica a post-influenzal or some other phenomenon? Time to re-examine the problem. Epidemiol Infect. 2009;137(4):449–55.
pubmed: 19144247
doi: 10.1017/S0950268808001891
Vilensky J, Gilman S. Encephalitis lethargica: could this disease be recognised if the epidemic recurred? Pract Neurol. 2006;6:360–7.
doi: 10.1136/jnnp.2006.106450
McCall S, Vilensky J, Gilman S, Taubenberger J. The relationship between encephalitis lethargica and influenza: a critical analysis. J Neurovirol. 2009;14(3):177–85.
doi: 10.1080/13550280801995445